Fig. 4.

Patients with high contralateral parenchymal enhancement (CPE) have a significantly better invasive disease-free survival (IDFS) and overall survival (OS) compared to patients with low CPE in both the biomarker-assessment study and the biomarker-discovery study. Patients had an ER-positive/HER2-negative breast cancer and received endocrine therapy. At 10 years, patients in the biomarker-assessment study (a, c) with high CPE had a 21% higher IDFS and a 16% higher 10-year OS compared to patients with low CPE (93% and 72% for IDFS, and 98% vs 82% for OS, respectively). In the biomarker-discovery study (b, d), patients with high CPE had a 16% higher IDFS and a 21% higher OS compared to patients with low CPE (96% vs 80% for IDFS, and 98% vs 77% for OS, respectively). The shaded areas correspond to the 95% confidence intervals of the inverse probability weighting-adjusted Kaplan-Meier survival curves